Sinovac vaccine has emergency use approval for people ages 3 to 17, according to the Chinese Embassy in Manila.
On Tuesday, the Chinese Embassy in Manila said that Sinovac COVID-19 vaccine had an emergency use approval for people aged 3 to 17 years old.
The Embassy noted in a statement posted on its official Facebook page that the Phase-II clinical trial showed that the said vaccine was at least 98.9% effective in producing antibodies, with higher efficacy than in population over 18 years old. The said experiment involved 180 volunteers within the age group.
Quoting Sinovac Biotech, the Embassy said that three months after vaccination, the production of antibodies among the population within the age group was 98.9% to 100% depending on the dosage of the vaccination.
“The result is better than on population aged above 18 years old, said Sinovac, noting that data suggests that the vaccine is stable and effective among young people,” the Embassy said in a statement.
It was last June when the World Health Organization (WHO) validated Sinovac Biotech’s CoronaVac COVID-19 vaccine, which made up the bulk of the Philippines’ COVID-19 vaccine supply, for people aged 18 years old and above.
In early July, Sinovac sought the approval of the Philippine Food and Drug Administration (FDA) for the authorization to use the said vaccine on people aged 3 to 17.
Meanwhile, the Food and Drug Administration’s official announcement on this matter had not yet been announced as of this writing.
What can you say about this? Let us know in the comments below.